943772-67-6

Basic information

• Product Name: 5-[4-(4-bromo-phenylcarbamoyl)-2-nitro-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester
• Synonyms: 5-[4-(4-bromo-phenylcarbamoyl)-2-nitro-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester
• CAS NO: 943772-67-6
• Molecular Weight: 568.448
• Mol File: 943772-67-6.mol

Chemical Properties

• CAS DataBase Reference: 5-[4-(4-bromo-phenylcarbamoyl)-2-nitro-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-[4-(4-bromo-phenylcarbamoyl)-2-nitro-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester(943772-67-6)
• EPA Substance Registry System: 5-[4-(4-bromo-phenylcarbamoyl)-2-nitro-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester(943772-67-6)

Safety Data

• Hazardous Substances Data: 943772-67-6(Hazardous Substances Data)

Upstream product

• 38818-50-7 4-chloro-3-nitro-benzoyl chloride 
• 106-40-1 4-bromo-aniline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 16066-91-4 5-iodo-1H-indole 
• 374818-66-3 tert-butyl 5-iodo-1H-indole-1-carboxylate 
• 943772-66-5 5-mercapto-indole-1-carboxylic acid tert-butyl ester 
• 329941-08-4 N-(4-bromo-phenyl)-4-chloro-3-nitro-benzamide 

Downstream Products

• 943772-68-7 5-[2-amino-4-(4-bromo-phenylcarbamoyl)-phenylsulfanyl]-indole-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ( HCV ) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, coformulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

ANTI-VIRAL COMPOUNDS

Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.